IDEXX Files 8-K on Financial Condition, Operations
Ticker: IDXX · Form: 8-K · Filed: Feb 5, 2024 · CIK: 874716
| Field | Detail |
|---|---|
| Company | Idexx Laboratories Inc /De (IDXX) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, corporate-filing
TL;DR
**IDXX just dropped an 8-K on financials, time to check their numbers.**
AI Summary
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on February 5, 2024, to report on its results of operations and financial condition, as well as to include financial statements and exhibits. This filing indicates that the company is providing updated financial information, which is crucial for investors to assess its current performance and make informed decisions about buying, holding, or selling IDXX stock.
Why It Matters
This filing signals that IDEXX is updating the market on its financial health, which directly impacts investor confidence and the stock's valuation.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not indicating any immediate adverse events or significant changes in company strategy.
Analyst Insight
A smart investor would review the detailed financial statements and results of operations that this 8-K refers to, once they become available, to understand IDEXX's current performance and financial health before making any investment decisions.
Key Numbers
- 000-19271 — Commission File Number (identifies IDEXX's registration with the SEC)
- 01-0393723 — IRS Employer Identification No. (identifies IDEXX for tax purposes)
- $0.10 — par value per share (the nominal value of IDEXX's common stock)
Key Players & Entities
- IDEXX Laboratories, Inc. (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for IDEXX Laboratories, Inc.
- NASDAQ Global Select Market (company) — exchange where IDEXX Common Stock is registered
- February 5, 2024 (date) — date of earliest event reported and filing date
- $0.10 (dollar_amount) — par value per share of Common Stock
FAQ
What is the primary purpose of this 8-K filing by IDEXX Laboratories, Inc.?
The primary purpose of this 8-K filing is to report on the company's results of operations and financial condition, and to furnish financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Results of Operations and Financial Condition' and 'ITEM INFORMATION: Financial Statements and Exhibits' sections.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 5, 2024, as stated in the 'Date of report (Date of earliest event reported): February 5, 2024' section.
What is the trading symbol and the exchange where IDEXX Laboratories, Inc.'s Common Stock is registered?
IDEXX Laboratories, Inc.'s Common Stock trades under the symbol IDXX and is registered on the NASDAQ Global Select Market, as detailed under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the state of incorporation for IDEXX Laboratories, Inc.?
IDEXX Laboratories, Inc. is incorporated in Delaware, as specified in the filing under 'State or other jurisdiction of incorporation: Delaware'.
What is the par value per share of IDEXX Laboratories, Inc.'s Common Stock?
The par value per share of IDEXX Laboratories, Inc.'s Common Stock is $0.10, as indicated in the 'Title of each class' section: 'Common Stock, $0.10 par value per share'.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-02-05 06:30:41
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share IDXX NASDAQ Glo
Filing Documents
- a53891750.htm (8-K) — 32KB
- a53891750ex99_1.htm (EX-99.1) — 1144KB
- idexxlogo.jpg (GRAPHIC) — 3KB
- 0001157523-24-000165.txt ( ) — 1371KB
- idxx-20240205.xsd (EX-101.SCH) — 4KB
- idxx-20240205_lab.xml (EX-101.LAB) — 22KB
- idxx-20240205_pre.xml (EX-101.PRE) — 16KB
- a53891750_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On February 5, 2024, IDEXX Laboratories, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled "IDEXX Laboratories Announces Fourth Quarter and Full Year 2023 Results," issued by the Company on February 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: February 5, 2024 By: /s/ Brian P. McKeon Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer 2